|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Azevedo AS, Follain G, Patthabhiraman S,
Harlepp S and Goetz JG: Metastasis of circulating tumor cells:
Favorable soil or suitable biomechanics, or both? Cell Adh Migr.
9:345–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giuliano M, Giordano A, Jackson S, De
Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, et
al: Circulating tumor cells as early predictors of metastatic
spread in breast cancer patients with limited metastatic
dissemination. Breast Cancer Res. 16:4402014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iinuma H, Watanabe T, Mimori K, Adachi M,
Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M
and Mori M: Clinical significance of circulating tumor cells,
including cancer stem-like cells, in peripheral blood for
recurrence and prognosis in patients with Dukes' stage B and C
colorectal cancer. J Clin Oncol. 29:1547–1555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thalgott M, Heck MM, Eiber M, Souvatzoglou
M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M,
Gschwend JE, et al: Circulating tumor cells versus objective
response assessment predicting survival in metastatic
castration-resistant prostate cancer patients treated with
docetaxel chemotherapy. J Cancer Res Clin Oncol. 141:1457–1464.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tjensvoll K, Nordgård O and Smaaland R:
Circulating tumor cells in pancreatic cancer patients: Methods of
detection and clinical implications. Int J Cancer. 134:1–8. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okubo K, Uenosono Y, Arigami T, Mataki Y,
Matsushita D, Yanagita S, Kurahara H, Sakoda M, Kijima Y, Maemura K
and Natsugoe S: Clinical impact of circulating tumor cells and
therapy response in pancreatic cancer. Eur J Surg Oncol.
43:1050–1055. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie ZB, Yao L, Jin C and Fu DL:
Circulating tumor cells in pancreatic cancer patients: Efficacy in
diagnosis and value in prognosis. Discov Med. 22:121–128.
2016.PubMed/NCBI
|
|
11
|
Barriere G, Riouallon A, Renaudie J,
Tartary M and Rigaud M: Mesenchymal characterization: Alternative
to simple CTC detection in two clinical trials. Anticancer Res.
32:3363–3369. 2012.PubMed/NCBI
|
|
12
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arnoletti JP, Zhu X, Almodovar AJ,
Veldhuis PP, Sause R, Griffith E, Corpus G, Chang JC, Fanaian N and
Litherland SA: Portal venous blood circulation supports
immunosuppressive environment and pancreatic cancer circulating
tumor cell activation. Pancreas. 46:116–123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tien YW, Kuo HC, Ho BI, Chang MC, Chang
YT, Cheng MF, Chen HL, Liang TY, Wang CF, Huang CY, et al: A high
circulating tumor cell count in portal vein predicts liver
metastasis from periampullary or pancreatic cancer: A high portal
venous CTC count predicts liver metastases. Medicine (Baltimore).
95:e34072016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Connor AA, McNamara K, Al-Sukhni E, Diskin
J, Chan D, Ash C, Lowes LE, Allan AL, Zogopoulos G, Moulton CA and
Gallinger S: Central, but not peripheral, circulating tumor cells
are prognostic in patients undergoing resection of colorectal
cancer liver metastases. Ann Surg Oncol. 23:2168–2175. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosenbaum MW, Cauley CE, Kulemann B, Liss
AS, Castillo CF, Warshaw AL, Lillemoe KD, Thayer SP and Pitman MB:
Cytologic characteristics of circulating epithelioid cells in
pancreatic disease. Cancer Cytopathol. 125:332–340. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bradley SE, Ingelfinger FJ, Bradley GP and
Curry JJ: The estimation of hepatic blood flow in man. J Clin
Invest. 24:890–897. 1945. View Article : Google Scholar
|
|
18
|
DeVita VT Jr, Young RC and Canellos GP:
Combination versus single agent chemotherapy: A review of the basis
for selection of drug treatment of cancer. Cancer. 35:98–110. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Del Monte U: Does the cell number 10(9)
still really fit one gram of tumor tissue? Cell Cycle. 8:505–506.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harb W, Fan A, Tran T, Danila DC, Keys D,
Schwartz M and Ionescu-Zanetti C: Mutational analysis of
circulating tumor cells using a novel microfluidic collection
device and qPCR assay. Transl Oncol. 6:528–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu L, Mao X, Imrali A, Syed F, Mutsvangwa
K, Berney D, Cathcart P, Hines J, Shamash J and Lu YJ: Optimization
and evaluation of a novel size based circulating tumor cell
isolation system. PLoS One. 10:e01380322015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miller MC, Doyle GV and Terstappen LW:
Significance of circulating tumor cells detected by the CellSearch
system in patients with metastatic breast colorectal and prostate
cancer. J Oncol. 2010:6174212010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goldstein NS and Bassi D: Cytokeratins 7,
17 and 20 reactivity in pancreatic and ampulla of vater
adenocarcinomas. Percentage of positivity and distribution is
affected by the cut-point threshold. Am J Clin Pathol. 115:695–702.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joosse SA and Pantel K: Biologic
challenges in the detection of circulating tumor cells. Cancer Res.
73:8–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Munz M, Baeuerle PA and Gires O: The
emerging role of EpCAM in cancer and stem cell signaling. Cancer
Res. 69:5627–5629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boyer B, Vallés AM and Edme N: Induction
and regulation of epithelial-mesenchymal transitions. Biochem
Pharmacol. 60:1091–1099. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu S, Liu S, Liu Z, Huang J, Pu X, Li J,
Yang D, Deng H, Yang N and Xu J: Classification of circulating
tumor cells by epithelial-mesenchymal transition markers. PLoS One.
10:e01239762015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bissolati M, Sandri MT, Burtulo G, Zorzino
L, Balzano G and Braga M: Portal vein-circulating tumor cells
predict liver metastases in patients with resectable pancreatic
cancer. Tumour Biol. 36:991–996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Catenacci DV, Chapman CG, Xu P, Koons A,
Konda VJ, Siddiqui UD and Waxman I: Acquisition of portal venous
circulating tumor cells from patients with pancreaticobiliary
cancers by endoscopic ultrasound. Gastroenterology.
149:1794–1803.e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang ZF, Cristofanilli M, Shao ZM, Tong
ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, et al:
Circulating tumor cells predict progression-free and overall
survival in Chinese patients with metastatic breast cancer,
HER2-positive or triple-negative (CBCSG004): A multicenter,
double-blind, prospective trial. Ann Oncol. 24:2766–2772. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shaffer DR, Leversha MA, Danila DC, Lin O,
Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, et
al: Circulating tumor cell analysis in patients with progressive
castration-resistant prostate cancer. Clin Cancer Res.
13:2023–2029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mavroudis D: Circulating cancer cells. Ann
Oncol. 21 Suppl 7:vii95–vii100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pantel K, Deneve E, Nocca D, Coffy A,
Vendrell JP, Maudelonde T, Riethdorf S and Alix-Panabières C:
Circulating epithelial cells in patients with benign colon
diseases. Clin Chem. 58:936–940. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dambrauskas Z, Svensson H, Joshi M,
Hyltander A, Naredi P and Iresjö BM: Expression of major
histocompatibility complex class I-related chain A/B (MICA/B) in
pancreatic carcinoma. Int J Oncol. 44:99–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu X, Rao GS, Groh V, Spies T, Gattuso P,
Kaufman HL, Plate J and Prinz RA: Major histocompatibility complex
class I-related chain A/B (MICA/B) expression in tumor tissue and
serum of pancreatic cancer: Role of uric acid accumulation in
gemcitabine-induced MICA/B expression. BMC Cancer. 11:1942011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Maeda S, Shinchi H, Kurahara H, Mataki Y,
Maemura K, Sato M, Natsugoe S, Aikou T and Takao S: CD133
expression is correlated with lymph node metastasis and vascular
endothelial growth factor-C expression in pancreatic cancer. Br J
Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nomura A, Banerjee S, Chugh R, Dudeja V,
Yamamoto M, Vickers SM and Saluja AK: CD133 initiates tumors,
induces epithelial-mesenchymal transition and increases metastasis
in pancreatic cancer. Oncotarget. 6:8313–8322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ding Q, Miyazaki Y, Tsukasa K, Matsubara
S, Yoshimitsu M and Takao S: CD133 facilitates
epithelial-mesenchymal transition through interaction with the ERK
pathway in pancreatic cancer metastasis. Mol Cancer. 13:152014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fidler IJ: Tumor heterogeneity and the
biology of cancer invasion and metastasis. Cancer Res.
38:2651–2660. 1978.PubMed/NCBI
|
|
42
|
Yachida S, Jones S, Bozic I, Antal T,
Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
